(20S)-1.alpha.-hydroxy-2.alpha.-methyl and 2.beta.-methyl-19-nor-vitamin D.sub.3 and their uses
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
Aug 22, 2006
Issued Date -
N/A
app pub date -
Jan 18, 2005
filing date -
Apr 22, 2002
priority date (Note) -
In Force
status (Latency Note)
Importance
Abstract
This invention discloses (20S)-1.alpha.-hydroxy-2.alpha.-methyl-19-nor-vitamin D.sub.3 and (20S)-1.alpha.-hydroxy-2.beta.-methyl-19-nor-vitamin D.sub.3 and pharmaceutical uses therefor. These compounds exhibit pronounced activity in arresting the proliferation of undifferentiated cells and inducing their differentiation to the monocyte thus evidencing use as an anti-cancer agent and for the treatment of skin diseases such as psoriasis as well as skin conditions such as wrinkles, slack skin, dry skin and insufficient sebum secretion. These compounds also have very significant calcemic activity and therefore may be used to treat immune disorders in humans as well as metabolic bone diseases such as osteoporosis.
First Claim
Family
International Classification(s)
Cited Art Landscape
Patent Citation Ranking
Advertisement
Advertisement
Advertisement
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully